Qing He Meng
Clinical Professor, Department of Pathology and Laboratory Medicine
University of Saskatchewan, Canada
Qing-He Meng received his medical education and had practiced as a physician for 8 years in China. He obtained his PhD in Clinical Chemistry from the University of Helsinki, Finland, in 1999. Following postdoctoral training in Clinical Chemistry at McMaster University, he assumed the position of Clinical Chemist/Assistant Professor at Royal University Hospital, University of Saskatchewan, Canada in 2003. He then moved to the Hospital for Sick Children, the University of Toronto and took the position as a Clinical Chemist and Assistant Professor in 2006. Currently he is Professor and Associate Director of Clinical Chemistry at Royal University Hospital, the University of Saskatchewan, Canada. Qing is a Diplomate of the American Board of Clinical Chemistry (ABCC) and Fellows of NACB (FACB) and the Canadian Academy of Clinical Biochemistry (FCACB). In addition to laboratory service, he is also actively involved in research and teaching at various levels. His research interests focus on lipids, diabetes, atherosclerosis, and cardiac markers. He has received substantial funds and has published over 50 papers in refereed journals. He serves as a reviewer for several journals and AACC annual meeting abstract committee. He is on the editorial board of Clinica Chimica Acta and Journal of Clinical and Experimental Pathology. He is also a Lab inspector for the CAP and the Chair of the Canadian Academy of Clinical Biochemistry. Currently he is the President of North American Chinese Clinical Chemist Association (NACCCA).
My research interests cover different aspects from basic study to translational and clinical investigations. The major areas of my research include 1). Diabetes and atherosclerosis: lipid metabolism, dislipidemia, atherosclerosis, nutrition, insulin resistance, diabetes and diabetic complications. 2). Clinical investigation on cardiovascular risk factors and risk markers: hyperlipidemia, hyperhomocysteinemia, hyperglycemia, and coronary artery disease; the role of cardiac biochemical markers in the diagnosis and prediction of ischemic myocardial injury. 3). Laboratory investigation: instrument evaluation, method development and validation, laboratory error and test interference investigation.